Antiretroviral agents are currently the only approved therapy for treatment of HIV dementia, but treatment response is frequently unsatisfactory or short-lived, or agents poorly tolerated in doses adequate for CNS penetration. The reason for the incomplete response may be that the pathophysiology of HIV-related cognitive impairment is initiated by the virus, but involves a complicated inflammatory cascade within the brain. Therefore, effective therapy needs to focus on these indirect mechanisms in addition to viral suppression. One hypothesis for the pathophysiology of dementia is that neurotoxic substances are produced by specific interactions between infected macrophages and astrocytes to damage and destroy neurons. In this schema, we are interested in the role of the lipid inflammatory mediator, platelet activating factor (PAF). This is a potent biological mediator that exerts its effects in as variety of cells and tissues and has been detected at high levels in the CSF of immune-suppressed HIV-1 infected patients with CNS dysfunction. Lexipafant is a PAF antagonist with high affinity for the PAF receptor with an excellent safety profile. Currently, controlled clinical trials of Lexipafant are under way in treatment of asthma, pancreatitis, ulcerative colitis and pre-operative ischemia. It has shown to be active via oral route and is well- tolerated in human volunteers using doses up to 750 mg bid. No prior clinical research has been reported with Lexipafant in HIV-infected individuals.
| Altekruse, Sean F; Shiels, Meredith S; Modur, Sharada P et al. (2018) Cancer burden attributable to cigarette smoking among HIV-infected people in North America. AIDS 32:513-521 |
| Salemi, Parissa; Skalamera Olson, Julie M; Dickson, Lauren E et al. (2018) Ossifications in Albright Hereditary Osteodystrophy: Role of Genotype, Inheritance, Sex, Age, Hormonal Status, and BMI. J Clin Endocrinol Metab 103:158-168 |
| Robert Braši?, James; Mari, Zoltan; Lerner, Alicja et al. (2018) Remission of Gilles de la Tourette Syndrome after Heat-Induced Dehydration. Int J Phys Med Rehabil 6: |
| Altman, Matthew C; Whalen, Elizabeth; Togias, Alkis et al. (2018) Allergen-induced activation of natural killer cells represents an early-life immune response in the development of allergic asthma. J Allergy Clin Immunol 142:1856-1866 |
| AIDS-defining Cancer Project Working Group of IeDEA, COHERE in EuroCoord (2018) Non-Hodgkin lymphoma risk in adults living with HIV across five continents. AIDS 32:2777-2786 |
| Juraschek, Stephen P; Miller 3rd, Edgar R; Appel, Lawrence J (2018) Orthostatic Hypotension and Symptoms in the AASK Trial. Am J Hypertens 31:665-671 |
| Elion, Richard A; Althoff, Keri N; Zhang, Jinbing et al. (2018) Recent Abacavir Use Increases Risk of Type 1 and Type 2 Myocardial Infarctions Among Adults With HIV. J Acquir Immune Defic Syndr 78:62-72 |
| Al-Sofiani, Mohammed E; Yanek, Lisa R; Faraday, Nauder et al. (2018) Diabetes and Platelet Response to Low-Dose Aspirin. J Clin Endocrinol Metab 103:4599-4608 |
| Grover, Surbhi; Desir, Fidel; Jing, Yuezhou et al. (2018) Reduced Cancer Survival Among Adults With HIV and AIDS-Defining Illnesses Despite No Difference in Cancer Stage at Diagnosis. J Acquir Immune Defic Syndr 79:421-429 |
| Grams, Morgan E; Sang, Yingying; Ballew, Shoshana H et al. (2018) Predicting timing of clinical outcomes in patients with chronic kidney disease and severely decreased glomerular filtration rate. Kidney Int 93:1442-1451 |
Showing the most recent 10 out of 1014 publications
